{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:08:33Z","timestamp":1793941713866,"version":"4.8.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22577153"],"award-info":[{"award-number":["22577153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20252069"],"award-info":[{"award-number":["BK20252069"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104772","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T06:08:33Z","timestamp":1786774113000},"page":"104772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Xin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6279-2793","authenticated-orcid":false,"given":"Guoshun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104772_b0005","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12672-025-04302-4","article-title":"Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions","volume":"17","author":"Wu","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.drudis.2026.104772_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/d41573-019-00201-w","article-title":"Breast cancer drug approvals by the US FDA from 1949 to 2018","volume":"19","author":"Leo","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104772_b0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41568-018-0001-z","article-title":"Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance","volume":"18","author":"Katzenellenbogen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104772_b0020","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12792","article-title":"Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation","volume":"5","author":"Fanning","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2026.104772_b0025","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6601629","article-title":"Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action","volume":"90","author":"Osborne","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104772_b0030","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3816\/CBC.2005.s.008","article-title":"The history and mechanism of action of fulvestrant","volume":"6","author":"Carlson","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.drudis.2026.104772_b0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00003088-200443080-00003","article-title":"Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer","volume":"43","author":"Robertson","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.drudis.2026.104772_b0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","article-title":"Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer","volume":"5","author":"Van Kruchten","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104772_b0045","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-023-01861-0","article-title":"Elacestrant: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104772_b0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40265-025-02266-x","article-title":"Imlunestrant: first approval","volume":"86","author":"Keam","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104772_b0055","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study","volume":"42","author":"Mart\u00edn","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104772_b0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0969-2126(01)00568-8","article-title":"Structural insights into the mode of action of a pure antiestrogen","volume":"9","author":"Pike","year":"2001","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2026.104772_b0065","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molcel.2023.06.028","article-title":"UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability","volume":"83","author":"Tsai","year":"2023","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104772_b0070","article-title":"Induced estrogen receptor SUMOylation drives SERD activity","author":"Hinterndorfer","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2026.104772_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112689","article-title":"Targeting estrogen receptor \u03b1 for degradation with PROTACs: a promising approach to overcome endocrine resistance","volume":"206","author":"Lin","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104772_b0080","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104772_b0085","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted protein degradation: from chemical biology to drug discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104772_b0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2013 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104772_b0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104772_b0100","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACs: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.drudis.2026.104772_b0105","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2026.104772_b0110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104772_b0115","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104772_b0120","unstructured":"U.S. Food and Drug Administration. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Published 1 May 2026. Accessed 9 May 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast."},{"key":"10.1016\/j.drudis.2026.104772_b0125","doi-asserted-by":"crossref","first-page":"16135","DOI":"10.1021\/acs.jmedchem.6c02076","article-title":"FDA approval of the first-ever PROTAC: vepdegestrant (ARV-471) marks a new era in targeted protein degradation","volume":"69","author":"Kumar","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104772_b0130","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202501111","article-title":"Insights into vepdegestrant (ARV-471): the first-in-class estrogen receptor proteolysis-targeting chimera approaching Food and Drug Administration approval for breast cancer","volume":"21","author":"Tang","year":"2026","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2026.104772_b0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsmedchemlett.0c00556","article-title":"Solution conformations shed light on PROTAC cell permeability","volume":"12","author":"Atilaw","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104772_b0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41570-023-00563-1","article-title":"Molecular chameleons in drug discovery","volume":"8","author":"Poongavanam","year":"2024","journal-title":"Nat Rev Chem"},{"key":"10.1016\/j.drudis.2026.104772_b0145","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and physicochemical features of oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104772_b0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41570-025-00784-6","article-title":"Lessons learned in linking PROTACs from discovery to the clinic","volume":"10","author":"Pike","year":"2026","journal-title":"Nat Rev Chem"},{"key":"10.1016\/j.drudis.2026.104772_b0155","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104772_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102825","article-title":"Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review","volume":"130","author":"Gheysen","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.drudis.2026.104772_b0165","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane radial ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2026.104772_b0170","unstructured":"ClinicalTrials.gov. Search results for ARV-471. Accessed 9 May 2026. https:\/\/clinicaltrials.gov\/search?term=ARV-471&viewType=Card."},{"key":"10.1016\/j.drudis.2026.104772_b0175","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104772_b0180","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.drudis.2026.104772_b0185","unstructured":"Guardant Health. Guardant Health receives FDA approval for Guardant360 CDx as a companion diagnostic for Arvinas and Pfizer\u2019s Veppanu (vepdegestrant) for patients with ER+\/HER2\u2212 advanced breast cancer with ESR1 mutations. Published 4 May 2026. Accessed 4 May 2026. https:\/\/investors.guardanthealth.com\/press-releases\/press-releases\/2026\/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-a-Companion-Diagnostic-for-Arvinas-and-Pfizers-VEPPANU-vepdegestrant-for-Patients-with-ERHER2\u2013Advanced-Breast-Cancer-with-ESR1-Mutations\/default.aspx."},{"key":"10.1016\/j.drudis.2026.104772_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104427","article-title":"Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+\/HER2\u2212 metastatic breast cancer","volume":"201","author":"Guerini-Rocco","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.drudis.2026.104772_b0195","doi-asserted-by":"crossref","first-page":"10503","DOI":"10.1021\/acs.jmedchem.5c01250","article-title":"RIPTACs for precision cancer therapy: a novel modality with the inspiration of HLD-0915 as the first candidate in clinical trials","volume":"68","author":"Ma","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104772_b0200","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2024.07.005","article-title":"Regulated induced proximity targeting chimeras\u2014RIPTACs\u2014a heterobifunctional small molecule strategy for cancer selective therapies","volume":"31","author":"Raina","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104772_b0205","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104772_b0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104772_b0215","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104772_b0220","doi-asserted-by":"crossref","first-page":"D1510","DOI":"10.1093\/nar\/gkae768","article-title":"PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters","volume":"53","author":"Ge","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2026.104772_b0225","unstructured":"PROTAC-DB 3.0. Accessed 9 May 2026. http:\/\/cadd.zju.edu.cn\/protacdb\/."},{"key":"10.1016\/j.drudis.2026.104772_b0230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104772_b0235","unstructured":"Astellas Pharma Inc. Astellas doses first patient in phase 3 study of setidegrasib (ASP3082) for KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. Published 15 April 2026. Accessed 10 May 2026. https:\/\/newsroom.astellas.com\/2026-04-15-astellas-doses-first-patient-in-phase-3-study-of-setidegrasib-for-kras-g12d-mutated-metastatic-pancreatic-ductal-adenocarcinoma."},{"key":"10.1016\/j.drudis.2026.104772_b0240","unstructured":"Ranok Therapeutics. Ranok Therapeutics announces initiation of patient dosing in a phase 1\/2 clinical trial of RNK05047, a first-in-class BRD4-targeting CHAMP\u2122 protein degrader. Published 24 August 2022. Accessed 28 July 2026. https:\/\/www.businesswire.com\/news\/home\/20220823005879\/en\/Ranok-Therapeutics-Announces-Initiation-of-Patient-Dosing-in-a-Phase-12-Clinical-Trial-of-RNK05047-a-First-in-Class-BRD4-Targeting-CHAMP-Protein-Degrader."},{"key":"10.1016\/j.drudis.2026.104772_b0245","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104772_b0250","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/diagnostics14171909","article-title":"Genetics, pathophysiology, and current challenges in Von Hippel-Lindau disease therapeutics","volume":"14","author":"G\u00f3mez-Virgilio","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.drudis.2026.104772_b0255","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41589-022-01177-2","article-title":"Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders","volume":"19","author":"Hanzl","year":"2023","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104772_b0260","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104772_b0265","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.molcel.2019.07.013","article-title":"Plasticity of the Cullin-RING ligase repertoire shapes sensitivity to ligand-induced protein degradation","volume":"75","author":"Mayor-Ruiz","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104772_b0270","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322563121","article-title":"Development of an orally bioavailable mSWI\/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer","volume":"121","author":"He","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104772_b0275","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/1538-7445.AM2023-432","article-title":"Abstract 432: mechanisms of acquired resistance to ARV-471, a novel PROTAC\u00ae estrogen receptor degrader","volume":"83","author":"Teh","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104772_b0280","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1038\/s41467-023-42233-2","article-title":"Expanding PROTACtable genome universe of E3 ligases","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104772_b0285","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1021\/acs.jmedchem.5c03330","article-title":"New PROTAC designs for targeted protein degradation in 2021\u20132025: novel E3 ligases and pre-PROTACs","volume":"69","author":"Peng","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104772_b0290","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104772_b0295","doi-asserted-by":"crossref","first-page":"15073","DOI":"10.1021\/jacs.1c04841","article-title":"Harnessing the E3 ligase KEAP1 for targeted protein degradation","volume":"143","author":"Wei","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104772_b0300","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1021\/jacs.1c00990","article-title":"DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras","volume":"143","author":"Zhang","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104772_b0305","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/jacs.1c03980","article-title":"Discovery of a covalent FEM1B recruiter for targeted protein degradation applications","volume":"144","author":"Henning","year":"2022","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104772_b0310","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41589-019-0304-8","article-title":"Harnessing the anti-cancer natural product nimbolide for targeted protein degradation","volume":"15","author":"Spradlin","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104772_b0315","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1038\/s41467-026-73252-4","article-title":"Discovery of a KLHL41 ligand for muscle specific protein degradation","volume":"17","author":"Yim","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104772_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118202","article-title":"Mighty mini-PROTACs: an emerging class of degraders","volume":"301","author":"Chen","year":"2026","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104772_b0325","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1021\/acscentsci.4c00286","article-title":"DCAF16-based covalent handle for the rational design of monovalent degraders","volume":"10","author":"Lim","year":"2024","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2026.104772_b0330","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41589-024-01668-4","article-title":"Template-assisted covalent modification underlies activity of covalent molecular glues","volume":"20","author":"Li","year":"2024","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104772_b0335","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1038\/s41467-025-63594-w","article-title":"Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9","volume":"16","author":"Hughes","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104772_b0340","unstructured":"Amphista Therapeutics. Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026. Published 21 April 2026. Accessed 10 May 2026. https:\/\/amphista.com\/amphista-therapeutics-presents-the-discovery-characterisation-and-chemical-structure-of-amx-883-an-orally-bioavailable-highly-potent-and-selective-dcaf16-degrader-of-brd9-at-aacr-2026\/."},{"key":"10.1016\/j.drudis.2026.104772_b0345","unstructured":"Arvinas. Arvinas announces positive phase 1 data for ARV-102 showing greater than 50% LRRK2 degradation in the CSF of patients with Parkinson\u2019s disease treated for 28 days. Published 18 March 2026. Accessed 10 May 2026. https:\/\/ir.arvinas.com\/news-releases\/news-release-details\/arvinas-announces-positive-phase-1-data-arv-102-showing-greater."},{"key":"10.1016\/j.drudis.2026.104772_b0350","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-025-01316-z","article-title":"Induced proximity-based therapeutic modalities","volume":"25","author":"King","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104772_b0355","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acscentsci.3c00395","article-title":"Proximity-based modalities for biology and medicine","volume":"9","author":"Liu","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2026.104772_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103774","article-title":"RIPTACs: a groundbreaking approach to drug discovery","volume":"28","author":"Ma","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104772_b0365","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/d41573-024-00103-6","article-title":"Extracellular targeted protein degrader removes antibodies in first test in humans","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:22:34Z","timestamp":1790094154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001777"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104772","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104772"}}